Description
Product Name: | Recombinant Mouse Tnfrsf9 Protein (His Tag) |
SKU: | RPES8429 |
Size: | 20μg |
Tag: | C-His |
Reactivity: | Mouse |
Expression Host: | Mammalian |
Accession: | P20334 |
Sequence: | Val24-Leu187 |
Calculated Molecular Weight: | 17.9 kDa |
Observed Molecular Weight: | 30-35 kDa |
Synonyms: | 4 1BB, 4 1BB ligand receptor, 4-1BB ligand receptor, 4-1BB Ligand Receptor T Cell, 4-1BB, mouse, homolog of, Antigen 4-1BB Homolog, CD 137, CD137, CD137 antigen, CDw137, HLDA VI, Homolog of mouse 4 1BB, ILA, induced by lymphocyte activation, ILA, Induced by lymphocyte activation, Interleukin activated receptor homolog of mouse Ly63, Ly63, mouse, homolog of, MGC2172, OTTHUMP00000044294, Receptor protein 4 1BB, T cell antigen 4 1BB homolog, T cell antigen ILA, T-cell antigen 4-1BB homolog, T-cell antigen ILA, TNF receptor superfamily member 9, TNFRSF9, TNR9, Tumor necrosis factor receptor superfamily member 9 |
Endotoxin: | < 1.0 EU/mg of the protein as determined by the LAL method |
Purity: | > 90% as determined by reducing SDS-PAGE. |
CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with an the tumor necrosis factor receptor–associated factors (TRAFs), the adaptor protein which mediates downstream signaling events including the activation of NF-kappaB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T-cell activation and growth, as well as monocyte proliferation and B-cell survival, and plays an important role in the amplification of T cell-mediated immune responses. In addition, CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors. Crosslinking of CD137 on activated T cells has shown promise in enhancing anti-tumor immune responses in murine models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials. Soluble forms of CD137 (sCD137) are generated by differential splicing. sCD137 can bind to CD137 ligand to antagonize the costimulatory activities of the membrane-bound CD137 and reduce T cell proliferation and IL-2 secretion.
Bio-activity: | Not validated for activity |
Formulation: | Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol. |
Reconstitution: | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis. |
Storage: | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
Shipping: | This product is provided as lyophilized powder which is shipped with ice packs. |